Cormorant Asset Management, LLC, Ten Percent Owner at Cellectar Biosciences, holds 8.32M shares in EyePoint Pharmaceuticals (Ticker: EYPT), holds 2.90M shares in Immuneering (Ticker: IMRX), holds 2.02M shares in Corbus Pharmaceuticals (Ticker: CRBP). Most recently, Cormorant Asset Management, LLC Bought ― shares of EyePoint Pharmaceuticals on May 08, 2024 for an estimated value of 10.08M.
What was Cormorant Asset Management, LLC’s latest transaction?
Cormorant Asset Management, LLC latest transaction was an Informative Buy of $10.08M.
What was Cormorant Asset Management, LLC's most profitable transaction?
Cormorant Asset Management, LLC’s most profitable transaction was an Informative Buy of AMAM stock on March 16, 2023. The return on the trade was 176.40%.
What is Cormorant Asset Management, LLC's role in Cellectar Biosciences?
Cormorant Asset Management, LLC's role in Cellectar Biosciences is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.